Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Medicamen Organics's revenue for the
six
months ended in Mar. 2026 was ₹47.78 Mil.
Its revenue for the trailing twelve months (TTM) ended in Mar. 2026 was ₹47.78 Mil.
Medicamen Organics's Revenue per Share for the
six
months ended in Mar. 2026 was ₹4.06.
Its Revenue per Share for the trailing twelve months (TTM) ended in Mar. 2026 was ₹4.06.
Warning Sign:
Medicamen Organics Ltd revenue per share is in decline over the past 12 months.
During the past 12 months, the average Revenue per Share Growth Rate of Medicamen Organics was -44.40% per year.
During the past 3 years, the average Revenue per Share Growth Rate was 0.50% per year.
During the past 5 years, the average Revenue per Share Growth Rate was 4.50% per year.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get other companies' revenue growth rate using Revenue per Share data.
During the past 6 years, Medicamen Organics's highest 3-Year average Revenue per Share Growth Rate was 24.40% per year. The lowest was 0.30% per year. And the median was 0.50% per year.
His favorite companies are stalwart, those growing between 10-20% a year.
Companies in cyclical industries may see their revenue fluctuate wildly in good years and bad years.
Be Aware
Revenue can be manipulated by changing the way how revenue is booked. Companies may book sales before the payment is received, or before the revenue is fully earned. These will be added to balance sheet items such as account payable or account receivables.
Medicamen Organics Revenue Related Terms
Medicamen Organics Revenue Historical Data
* Premium members only.
The historical data trend for Medicamen Organics's Revenue can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Drug Manufacturers - Specialty & Generic subindustry, Medicamen Organics's Revenue, along with its competitors' market caps and Revenue data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Medicamen Organics Revenue vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Medicamen Organics's Revenue distribution charts can be found below:
* The bar in red indicates where Medicamen Organics's Revenue falls into.
Also referred as sales, revenue is income that a company receives from its normal business activities, usually from the sale of goods and services to customers. Revenue is often referred to as the "top line" due to its position on the income statement at the very top.
Revenue for the trailing twelve months (TTM) ended in Mar. 2026 adds up the semi-annually data reported by the company within the most recent 12 months, which was ₹47.78 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Medicamen Organics (NSE:MEDIORG) has a Revenue of ₹47.78 Mil as of Mar. 2026. Revenue is the total amount a company generates as sales through its operations. View historical data on Medicamen Organics and its competitors.
Is Medicamen Organics' Revenue too high?
Medicamen Organics' current Revenue is ₹47.78 Mil. Overall, Medicamen Organics has a GF Score™ of 26/100, reflecting its overall financial health beyond just this single metric.
How does Medicamen Organics' Revenue compare to ZTS?
Medicamen Organics' Revenue of ₹47.78 Mil can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Revenue for a Drug Manufacturers company?
A good Revenue depends on the Drug Manufacturers industry context. However, Revenue should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Revenue mean?
A high Revenue can signal that a stock is expensive relative to its fundamentals. Revenue is the total amount a company generates as sales through its operations. View historical data on Medicamen Organics and its competitors. Medicamen Organics's current Revenue is ₹47.78 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Medicamen Organics stock overvalued right now?
Medicamen Organics (NSE:MEDIORG) has a current Revenue of ₹47.78 Mil. The current Revenue is ₹47.78 Mil. Medicamen Organics' overall GF Score™ is 26/100 with 10 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Revenue calculated?
Revenue is calculated from a company's financial statements. For Medicamen Organics (NSE:MEDIORG), the current Revenue is ₹47.78 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Medicamen Organics Ltd develops, manufactures, and distributes a wide range of pharmaceutical dosage forms, including Tablets, Capsules, Oral Liquids, Ointments, Gel, Syrups, Suspension and Dry powders. The company operates two WHO Good Manufacturing Practice certified facilities in India, producing products for both domestic and international clients. It provides contract manufacturing and loan license services to various pharmaceutical companies and exports to several countries across Africa, CIS, and South Asia. The principal source of revenue is through the manufacturing, export, and contract services focused on generic and branded pharmaceutical formulations.
26GF Score
Get the complete analysis for NSE:MEDIORG
Revenue is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
NSE:MEDIORG has been successfully added to your 
